Skip to content
Biotechnology

BioMed X Launches a New Call for Application in Autoimmune Disease Research

The BioMed X Institute 3 mins read

A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease.

HEIDELBERG, GERMANY / ACCESSWIRE / November 7, 2023 / BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.

Current therapeutic strategies for autoimmune diseases primarily focus on broadly suppressing the immune response, with significant side effects. More importantly, none of these treatments address one of the root causes of the disease, the autoreactive plasma cells that produce antibodies targeting self-antigens. By exploring the deep biology of human autoreactive plasma cells to identify biomarkers that distinguish them from their physiological counterparts, this project aims to identify new therapeutic strategies to selectively eliminate these cells in patients suffering from autoimmune diseases.

"Immunology - including autoimmunity - is one of our R&D focus areas at our BioMed X Institutes in Heidelberg, New Haven, and our XSeed Labs in Ridgefield. Currently, we are hosting five immunology research teams at different stages of development. We are excited to extend our immunology research capabilities with this new project in the field of autoreactive plasma cells," explains Christian Tidona, Founder and Managing Director of the BioMed X Institute.

This new research group will be located at the BioMed X Institute in Heidelberg, Germany. Each BioMed X project is a collaboration with a leading pharmaceutical company. To learn more about this project and how to apply, visit the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C02. The deadline for applying is January 7, 2023.

About BioMed X

BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information:

Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

Related Images

SOURCE: BioMed X Institute

.


View source version on accesswire.com:
https://www.accesswire.com/800139/biomed-x-launches-a-new-call-for-application-in-autoimmune-disease-research

More from this category

  • Biotechnology, Business Company News
  • 26/03/2025
  • 10:11
Jane Morgan Management

LTR Pharma Multi-Market Strategy and Regulatory Update

26 March 2025 – LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to provide an update to the Company’s commercial and regulatory processes, highlighting the strong progress that has been made toward the global commercialisation and approvals for its innovative intranasal erectile dysfunction (ED) treatment, SPONTAN®. Highlights Successful FDA pre-IND meeting has outlined a clear approval pathway for SPONTAN® in the United States. Introduction of new product, Roxus®, a vardenafil-based nasal spray targeting the personalised healthcare market via US compounding pharmacy channel. Recognition at USANZ conference – SPONTAN® has been shown to deliver 470% faster absorption than…

  • Contains:
  • Biotechnology, Business Company News
  • 19/03/2025
  • 11:22
Jane Morgan Management

BlinkLab Expands Autism Diagnostics to Adults – New Collaboration with VU Amsterdam and NAR

19 March 2025 | BlinkLab Limited (ASX: BB1) (“BlinkLab” or the “Company”) is pleased to announce its newest partnership with Vrije Universiteit Amsterdam (VU Amsterdam) and the Netherlands Autism Register (NAR) in order to advance research on autism detection in adults. This study will complement BlinkLab’s ongoing FDA-registration trial for the diagnossis of autism in children, and is a significant step in expanding clinical applications for the AI-powered diagnostic tool that BlinkLab has developed. Highlights New study evaluating BlinkLab's autism detection smartphone app in adults, including adult-diagnosed autism. A focus on underdiagnosed populations, particularly women with autism, whom have historically…

  • Contains:
  • Biotechnology
  • 18/03/2025
  • 08:55
OncoSil Medical Limited (ASX:OSL)

OncoSil Medical (ASX:OSL) appoints Ms Shelley Steyn as Chief Financial Officer

Sydney, Australia – 18 March 2025: The Board of pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce the appointment of Ms Shelley Steyn as Chief Financial Officer (“CFO”) with effect from 5 May 2025. The appointment reflects OncoSil’s ongoing commitment to strengthening its leadership. As OncoSil enters a critical phase of development Ms Steyn’s appointment at Chief Financial Officer will bolster the Company’s ability to drive the Company’s strategic priorities. Ms Steyn brings to OncoSil extensive experience with more than 17 years in senior accounting, commercial and financial analysis and audit…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.